SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

TuHURA Biosciences Reports Preliminary Responses in IFx-2.0 Study

The company said the first three patients showed major objective tumor responses at six months in an open-label study of IFx-2.0 alongside Keytruda for first-line treatment of metastatic Merkel cell carcinoma.

HURA

Related stories